Multifunctional peptide-based nanosystems for improving delivery and molecular imaging

Current Opinion in Molecular Therapeutics

Volumn 10, Issue 2, 2008, Pages 132-139

  Emerich, D F ^a   Thanos, C G ^b  

^a InCytu Inc   (United States)

^b BROWN UNIVERSITY   (United States)

Author keywords

Drug delivery; Molecular diagnostics; Nanomedicine; Nanoparticle; Peptide

Indexed keywords

CELL PENETRATING PEPTIDE; DENDRIMER; DOXORUBICIN; HEXAPEPTIDE; LIPOSOME; LOPERAMIDE; MELPHALAN; NANOCRYSTAL; NANOPARTICLE; NANOTUBE; PEPTIDE; POLYGLACTIN; POLYMER; SOLID LIPID NANOPARTICLE;

CARDIOVASCULAR SYSTEM; CELL COMPARTMENTALIZATION; CERAMICS; CLINICAL RESEARCH; DIAGNOSTIC PROCEDURE; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG SOLUBILITY; DRUG TARGETING; HUMAN; HYDROGEL; IMAGING SYSTEM; MICELLE; MOLECULAR IMAGING; NANOMEDICINE; NANOTECHNOLOGY; NONHUMAN; PARTICLE SIZE; REVIEW;

DIAGNOSIS; DRUG DELIVERY SYSTEMS; NANOPARTICLES; PEPTIDES;

EID: 41849127472     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (73)

1. Pinto Reis C, Neufeld RJ, Ribeiro AJ, Veiga F: Nanoencapsulation II. Biomedical applications and current status of peptide and protein nanoparticulate delivery systems. Nanomedicine (2006) 2(2):53-65. • Provides an excellent overview of the use of nanoparticles for delivery of peptides.
2. Galindo-Rodriguez SA, Allemann E, Fessi H, Doelker E: Polymeric nanoparticles for oral delivery of drugs and vaccines: A critical evaluation of in vivo studies. Crit Rev Ther Drug Carr Syst (2005) 22(5):419-464.
3. Emerich DF, Thanos CG: Targeted nanoparticle-based drug delivery and diagnosis. J Drug Targeting (2007) 15(3):163-183.
4. McKinnie J: Nanobiotechnology offers a promising solution to overcoming common drug delivery failures. Drug Deliv Technol (2005) 5(7):11-15.
5. Foged C, Nielsen HM: Cell-penetrating peptides for drug delivery across membrane barriers. Expert Opin Drug Deliv (2008) 5(1):105-117.
6. Cai W, Chen X: Preparation of peptide-conjugated quantum dots for tumor vasculature-targeted imaging. Nat Protoc (2008) 3(1):89-96.
7. Jiang W, Kim BY, Rutka JT, Chan WC: Advances and challenges of nanotechnology-based drug delivery systems. Expert Opin Drug Deliv (2007) 4(6):621-633.
8. Pinto RC, Neufeld RJ, Ribeiro AJ, Veiga F: Nanoencapsulation II. Biomedical applications and current status of peptide and protein nanoparticulate delivery systems. Nanomedicine (2006) 2(2):53-65.
9. Mayer C: Nanocapsules as drug delivery systems. Int J Artif Organs (2005) 28(11):1163-1171.
10. Yih TC, Al-Fandi M: Engineered nanoparticles as precise drug delivery systems. J Cell Biol (2006) 97(6):1184-1190.
11. Hauck TS, Chan WC: Gold nanoshells in cancer imaging and therapy: Towards clinical application. Nanomedicine (2007) 2(5):735-738.
12. Choi MR, Stanton-Maxey KJ, Stanley JK, Levin CS, Bardhan R, Akin D, Badve S, Sturgis J, Robinson JP, Bashir R, Halas NJ, Clare SE: A cellular trojan horse for delivery of therapeutic nanoparticles into tumors. Nano Lett (2007) 7(12):3759-3765.
13. Niederhafner P, Sebestik J, Jezek J: Peptide dendrimers. J Pept Sci (2005) 11(12):757-788.
14. Ta HT, Dass CR, Dunstan DE: Injectable chitosan hydrogels for localized cancer therapy. J Control Release (2008):doi:10.1016/j. jconrel.2007.11.018.
15. Martins S, Sarmento B, Ferreira DC, Souto EB: Lipid-based colloidal carriers for peptide and protein delivery-liposomes versus lipid nanocarriers. Int J Nanomedicine (2007) 2(4):595-607.
16. Rawat A, Vaidya B, Khatri K, Goyal AK, Gupta PN, Mahor S, Paliwal R, Rai S, Vyas SP: Targeted intracellular delivery of therapeutics: An overview. Pharmazie (2007) 62(9):643-658.
17. Nasongkia N, Bey E, Ren J, Ai H, Khemtong C, Guthi JS, Chin SF, Sherry AD, Boothman DA, Gao J: Multifunctional polymeric micelles as cancer-targeted, MRI-ultrasensitive drug delivery systems. Nano Lett (2006) 6(11):2427-2430.
18. Rabinow BE: Nanosuspensions in drug delivery. Nat Rev Drug Discov (2004) 3(9):785-796.
19. Prato M, Kostarelos K, Bianco A: Functionalized carbon nanotubes in drug design and discovery. Acc Chem Res (2008) 41(1):60-68.
20. Yang J, Wang K, Driver J, Yang J, Barron AR: The use of fullerene substituted phenylalanine amino acid as a passport for peptides through cell membranes. Org Biomol Chem (2007) 5(2):260-266.
21. Delie F, Blanco-Prieto MJ: Polymeric particulates to improve oral bioavailability of peptide drugs. Molecules (2005) 10(1):65-80.
22. Sarmento B, Martins S, Ferreira D, Souto EB: Oral insulin delivery by means of solid lipid nanoparticles. Int J Nanomedicine (2007) 2(4):743-749.
23. Labhasetwar V: Nanotechnology for drug and gene therapy: The importance of understanding molecular mechanisms of delivery. Curr Opin Biotechnol (2005) 16(6):674-680.
24. Panyam J, Labhasetwar V: Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev (2003) 55(3):329-347.
25. Moghimi SM, Hunter AC, Murray JC: Long-circulating and targetspecific nanoparticles: Theory to practice. Pharmacol Rev (2001) 53(2):283-318.
26. Moghimi SM, Hunter AC, Murray JC: Nanomedicine: Current status and future prospects. FASEB J (2005) 19(3):311-330.
27. Akerman ME, Chan WC, Laakkonen P, Bhatia SN, Ruoslahti E: Nanocrystal targeting in vivo. Proc Natl Acad Sci USA (2002) 99(20):12617-12621.
28. Ballou B, Lagerholm BC, Ernst LA, Bruchez MP, Waggoner AS: Noninvasive imaging of quantum dots in mice. Bioconjug Chem (2004) 15(1):79-86.
29. Gao X, Cui Y, Levenson RM, Chung LW, Nie S: In vivo cancer targeting and imaging with semiconductor quantum dots. Nat Biotechnol (2004) 22(8):969-976.
30. Kim S, Lim YT, Soltesz EG, De Grand AM, Lee J, Nakayama A, Parker JA, Mihaljevic T, Laurence RG, Dor DM, Cohn LH et al: Near-infrared fluorescent type II quantum dots for sentinel lymph node mapping. Nat Biotechnol (2004) 22(1):93-97.
31. Winter PM, Caruthers SD, Kassner A, Harris TD, Chinen LK, Allen JS, Lacy EK, Zhang H, Robertson JD, Wickline SA, Lanza GM: Molecular imaging of angiogenesis in nascent Vx-2 rabbit tumours using a novel αvβ3- targeted nanoparticle and 1.5 tesla magnetic resonance imaging. Cancer Res (2003) 63(18):5838-5843.
32. Moghimi SM, Bonnemain B: Subcutaneous and intravenous delivery of diagnostic agents to the lymphatic system: Applications in lymphoscintigraphy and indirect lymphography. Adv Drug Deliv Rev (1999) 37(1-3):295-312.
33. Jones AT: Gateways and tools for drug delivery: Endocytic pathways and the cellular dynamics or cell penetrating peptides. Int J Pharm (2008):354(1-2):34-38.
34. Fawell S, Seery J, Daikh Y, Moore C, Chen LL, Pepinsky B, Barsoum J: Tat-mediated delivery of heterologous proteins into cells. Proc Natl Acad Sci USA (1994) 91(2):664-668.
35. Wender PA, Mitchell DJ, Pattabiraman K, Pelkey ET, Steinman L, Rothbard JB: The design, synthesis and evaluation of molecules that enable or enhance cellular uptake: Peptoid molecular transporters. Proc Natl Acad Sci USA (2000) 97(24):13003-13008.
36. Pooga M, Hällbrink M, Zorko M, Langel U: Cell penetration by transportan. FASEB J (1998) 12(1):67-77.
37. Derossi D, Joliot AH, Chassaing G, Prochiantz A: The third helix of the antennapedia homeodomain translocates through biological membranes. J Biol Chem (1994) 269(14):10444-10450.
38. Sawant RM, Hurley JP, Salmaso S, Kale A, Tolcheva E, Levchenko TS, Torchilin VP: "Smart" drug delivery systems: Double-targeted pH-responsive pharmaceutical nanocarriers. Bioconjug Chem (2006) 17(4):943-949. •• This study demonstrated the potential of multifunctional control of drug delivery.
39. Deshayes S, Morris M, Heitz F, Divita G: Delivery of proteins and nucleic acids using a non-covalent peptide-based strategy. Adv Drug Deliv Rev (2008) 60(4-5):537-547.
40. Langlois MA, Boniface C, Wang G, Alluin J, Salvaterra PM, Puymirat J, Rossi JJ, Lee NS: Cytoplasmic and nuclear retained DMPK mRNAs are targets for RNA interference in myotonic dystrophy cells. J Biol Chem (2005) 280(17):16949-16954.
41. Crombez L, Charnet A, Morris MC, Aldrian-Herrada G, Heitz F, Divita G: A non-covalent peptide-based strategy for siRNA delivery. Biochem Soc Trans (2007) 35(1):44-46. • This is an important demonstration of in vivo intracellular peptide-based siRNA delivery.
42. Zhang N, Chittasupho C, Duangrat C, Siahaan TJ, Berkland C: PLGA nanoparticle-peptide conjugate effectively targets intercellular cell-adhesion molecule-1. Bioconjug Chem (2008) 19(1):145-152.
43. Tosi G, Constantino L, Rivasi F, Ruozi B, Leo E, Vergoni AV, Tacchi R, Bertolini A, Vandelli MA, Forni F: Targeting the central nervous system: In vivo experiments with peptide-derivatized nanoparticles loaded with loperamide and rhodamine-123. J Control Release (2007) 122(1):1-9. •• Overcoming the BBB via systemic delivery is a 'holy grail' of drug delivery. This nanoparticle-peptide system delivered therapeutically effective concentrations of an opiate.
44. Eliceiri BP, Cheresh DA: The role of αv integrins during angiogenesis: Insights into potential mechanisms of action and clinical development. J Clin Invest (1999) 103(9):1227-1230.
45. Kim S, Bell K, Mousa SA, Varner JA: Regulation of angiogenesis in vivo by ligation of integrin α5β1 with the central cell-binding domain of fibronectin. Am J Pathol (2000) 156(4):1345-1362.
46. Pasqualini R, Arap W, McDonald DM: Probing the structural and molecular diversity of tumor vasculature. Trend Mol Med (2002) 8(12):563-571.
47. St Croix B, Rago C, Velculescu V, Traverso G, Romans KE, Montgomery E, Lal A, Riggins GJ, Lengauer C, Vogelstein B, Kinzler KW: Genes expressed in human tumor endothelium. Science (2000) 289(5482):1197-1202. •• This important study described at the genomic level the differences in normal endothelium and endothelium derived from colorectal malignancies.
48. Assa-Munt N, Jia X, Laakkonen P, Ruoslahti E: Solution structures and integrin binding activities of an RGD peptide with two isomers. Biochemistry (2001) 40(8):2373-2378.
49. Arap W, Pasqualini R, Ruoslahti E: Cancer treatment by targeted drug delivery to tumour vasculature in a mouse model. Science (1998) 279(5349):377-380. • A significant step toward targeted drug delivery to tumors using peptides demonstrated an effect in xenografts.
50. Zitzmann S, Ehemann V, Schwab M: Arginine-glycine-aspartic acid (RGD)-peptide binds to both tumor and tumor-endothelial cells in vivo. Cancer Res (2002) 62(18):5139-5143.
51. Turunen MP, Puhakka HL, Koponen JK, Hiltunen MO, Rutanen J, Leppänen O, Turunen AM, Närvänen A, Newby AC, Baker AH, Ylä-Herttuala S: Peptide-retargeted adenovirus encoding a tissue inhibitor of metalloproteinase-1 decreases restenosis after intravascular gene transfer. Mol Ther (2002) 6(3):306-312.
52. Curnis F, Sacchi A, Corti A: Improving chemotherapeutic drug penetration in tumours by vascular targeting and barrier alteration. J Clin Invest (2002) 110(4):475-482.
53. Hood JD, Bednarski M, Frausto R, Guccione S, Reisfeld RA, Xiang R, Cheresh DA: Tumor regression by targeted gene delivery to the neovasculature. Science (2002) 296(5577):2404-2407. • This cationic nanoparticle-coupled integrin ligand successfully carried a mutant Raf gene to the tumor blood supply and led to regression of metastatic tumors.
54. Pastorino F, Brignole C, Marimpietri D, Cilli M, Gambini C, Ribatti D, Longhi R, Allen TM, Corti A, Ponzoni M: Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy. Cancer Res (2003) 63(21):7400-7409.
55. Roeder GE, Parish JL, Stern PL, Gaston K: Herpes simplex virus VP22-human papillomavirus E2 fusion proteins produced in mammalian or bacterial cells enter mammalian cells and induce apoptotic cell death. Biotechnol Appl Biochem (2004) 40(2):157-165.
56. Green KL, Southgate TD, Mulryan K, Fairbairn LJ, Stern PL, Gaston K: Diffusible VP22-E2 protein kills bystander cells and offers a route for cervical cancer gene therapy. Hum Gene Ther (2006) 17(2):147-157.
57. Zavaglia D, Normand N, Brewis N, O'Hare P, Favrot MC, Coll JL: VP22-mediated and light-activated delivery of an anti-craf1 antisense oligonucleotide improves its activity after intratumoral injection in nude mice. Mol Ther (2003) 8(5):840-845.
58. Liu Y, Shipton MK, Ryan J, Kaufman ED, Franzen S, Feldheim DL: Synthesis, stability, and cellular internalization of gold nanoparticles containing mixed peptide-poly(ethylene glycol) monolayers. Anal Chem (2007) 79(6):2221-2229.
59. Kim Y, Lillo AM, Steiniger SC, Liu Y, Ballatore C, Anichini A, Mortarini R, Kaufman GF, Zhou B, Felding-Haberman B, Janda KD: Targeting heat shock proteins on cancer cells: Selection, characterization, and cell-penetrating properties of a peptidic GRP78 ligand. Biochemistry (2006) 45(31):9434-9444.
60. Lu S, Tager LA, Chitale S, Riley LW: A cell-penetrating peptide derived from mammalian cell uptake protein of Mycobacterium tuberculosis. Anal Biochem (2006) 353(1):7-14.
61. Derfus AM, Chen AA, Min DH, Ruoslahti E, Bhatia SN: Targeted quantum dot conjugates for siRNA delivery. Bioconjug Chem (2007) 18(5):1391-1396. • This study used tumor-homing peptides to deliver siRNA therapeutics inside of tumor cells. If this approach can be used to target specific oncogenes it might lead to technologies that can treat and image metastatic cancer.
62. Rhyner MN, Smith AM, Gao X, Mao H, Yang L, Nie S: Quantum dots and multifunctional nanoparticles: New contrast agents for tumor imaging. Nanomedicine (2006) 1(2):209-217.
63. Xing Y, Smith AM, Agrawal A, Ruan G, Nie S: Molecular profiling of single cancer cells and clinical tissue specimens with semiconductor quantum dots. Int J Nanomedicine (2006) 1(4):473-481.
64. Hild WA, Breunig M, Goepferich A: Quantum dots- nano-sized probes for the exploration of cellular and intracellular targeting. Eur J Pharm Biopharm (2008) 68(2):153-168.
65. Bruchez M, Moronne M, Gin P, Weiss S, Alivisatos AP: Semiconductor nanocrystals as fluorescent biological labels. Science (1998) 281(5385):2013-2016.
66. Chan WC, Maxwell DJ, Gao X, Bailey RE, Han M, Nie S: Luminescent quantum dots for multiplexed biological detection and imaging. Curr Opin Biotechnol (2002) 13(1):40-46.
67. Zhou M, Nakatani E, Gronenberg LS, Tokimoto T, Wirth MJ, Hruby VJ, Roberts A, Lynch RM, Ghosh I: Peptide-labeled quantum dots for imaging GPCRs in whole cells and as single molecules. Bioconjug Chem (2007) 18(2):323-332.
68. Cai W, Shin DW, Chen K, Gheysens O, Cao Q, Wang SX, Gambhir SS, Chen X: Peptide-labeled near-infrared quantum dots for imaging tumor vasculature in living subjects. Nano Lett (2006) 6(4):669-676. •• This study provides proof-of-principle for using peptide-decorated quantum dots to label and image the vasculature around and within glioblastoma tumors in mice. These RGD peptide-labeled quantum dots were injected intravenously and provided excellent contrast. This approach might significantly enhance the ongoing development of cancer drugs targeting tumor vasculature.
69. Biju V, Muraleedharan D, Nakayama K, Shinohara Y, Itoh T, Baba Y, Ishikawa M: Quantum dot-insect neuropeptide conjugates for fluorescence imaging, transfection, and nucleus targeting of living cells. Langmuir (2007) 23(20):10254-10261. •• A Drosophila neuropeptide (allatostatin 1) was used to transfect carcinoma cells and transport conjugated quantum dots inside the cytoplasm and the nucleus of the cells. The ability to target specific intracellular compartments could represent a significant therapeutic advance over conventional cell membrane- and cytoplasm-based approaches.
70. Nitin N, Javier DJ, Richards-Kortum R: Oligonucleotide-coated metallic nanoparticles as a flexible platform for molecular imaging agents. Bioconjug Chem (2007) 18(6):2090-2096.
71. Medarova Z, Pham W, Kim Y, Dai G, Moore A: In vivo imaging of tumor response to therapy using a dual-modality imaging strategy. Int J Cancer (2006) 118(11):2796-1802. •• Superparamagnetic iron oxide nanoparticles modified with a dye and peptides recognized adenocarcinomas in vivo and were used to track the tumor response to chemotherapy in real time. If fully realized, this technology could significantly reduce the time and cost of developing future chemotherapeutics.
72. Gan ZF, Jiang JS, Yang Y, Du B, Qian M, Zhang P: Immobilization of homing peptide on magnetite nanoparticles and its specificity in vitro. J Biomed Mater Res A (2008) 84(1):10-18.
73. Kim JS, Rieter WJ, Taylor KM, An H, Lin W, Lin W: Self-assembled hybrid nanoparticles for cancer-specific multimodal imaging. J Am Chem Soc (2007) 129(29):8962-8963. •• This is a fascinating new approach using nanoparticles with both a tumor homing property and a capacity to amplify themselves at the target site. Conceivably, this amplification can someday be used to enhance tumor imaging and carry chemotherapeutic drugs with 'as needed' drug delivery.